Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Dermatology

Diabetes

Digital Health

Eyecare

Gene Therapy

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pediatrics

Plaque Psoriasis

Secondary Progressive Multiple Sclerosis: Patient Impact and Coverage Implications for New Therapies

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Vaccines: 2023 Year in Review

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

PBM Leaders

Subscribe

Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.

Videos

Andel, principal of CommonHealth Solutions LLC, weighed in on potential strategies and challenges for Part D plans in navigating medication formulary limitations during catastrophic coverage phases in this second part of a two-part video series.

Melissa Andel Gives Insights on Potential Changes to Part D Formularies | AMCP 2024

Articles

One result of the Inflation Reduction Act shifting a greater proportion the cost of drugs during the catastrophic phase of coverage to the Part D plans result may be narrower formularies.

IRA Will Shift Cost Burn to Part D Plans in 2025, Says Melissa Andel | AMCP 2024

Adam Colborn outlined four trends in state-level action on pharmacy benefit managers (PBMs) and drugs in an interview prior to this presentation at the annual meeting of Academy of Managed Care Pharmacy (AMCP) today.

It's Not Just Congress. There's Plenty of State-Level Action on PBMs, Drug Costs and Prices | AMCP 2024

Psychiatrists and psychologists also had lower in-network reimbursement rates.

Out-of-Network Use 10 Times Higher for Psychological Care vs. Medical Care APA-Funded Study Finds

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

Twitter

LinkedIn

Resource Centers

Eye Care

Spotlight

2023 PBMI Annual National Conference

2024 Emerging Leader Nominations

AMCP Annual

ASRS

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

Jesse C. Dresser

Articles